Champions Oncology Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Champions Oncology's earnings have been declining at an average annual rate of -52.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 12% per year.
Belangrijke informatie
-52.7%
Groei van de winst
-50.3%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 21.5% |
| Inkomstengroei | 12.0% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -6.6% |
| Laatste winstupdate | 31 Jul 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth
Oct 24
It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)
Jun 14Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Opbrengsten en kosten
Hoe Champions Oncology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Jul 24 | 52 | -3 | 18 | 8 |
| 30 Apr 24 | 50 | -7 | 18 | 10 |
| 31 Jan 24 | 49 | -10 | 18 | 10 |
| 31 Oct 23 | 50 | -10 | 18 | 11 |
| 31 Jul 23 | 53 | -8 | 18 | 11 |
| 30 Apr 23 | 54 | -5 | 17 | 12 |
| 31 Jan 23 | 54 | -3 | 17 | 11 |
| 31 Oct 22 | 54 | 0 | 16 | 10 |
| 31 Jul 22 | 52 | 0 | 16 | 10 |
| 30 Apr 22 | 49 | 1 | 15 | 9 |
| 31 Jan 22 | 47 | 0 | 14 | 9 |
| 31 Oct 21 | 44 | 0 | 14 | 9 |
| 31 Jul 21 | 43 | 0 | 13 | 8 |
| 30 Apr 21 | 41 | 0 | 12 | 7 |
| 31 Jan 21 | 39 | -1 | 12 | 7 |
| 31 Oct 20 | 37 | -2 | 12 | 6 |
| 31 Jul 20 | 35 | -1 | 11 | 6 |
| 30 Apr 20 | 32 | -2 | 11 | 6 |
| 31 Jan 20 | 31 | 0 | 10 | 5 |
| 31 Oct 19 | 29 | -1 | 9 | 5 |
| 31 Jul 19 | 28 | -1 | 8 | 5 |
| 30 Apr 19 | 27 | 0 | 8 | 5 |
| 31 Jan 19 | 24 | 0 | 7 | 5 |
| 31 Oct 18 | 23 | 0 | 7 | 4 |
| 31 Jul 18 | 21 | 0 | 6 | 4 |
| 30 Apr 18 | 20 | -1 | 7 | 4 |
| 31 Jan 18 | 19 | -3 | 7 | 4 |
| 31 Oct 17 | 18 | -5 | 7 | 4 |
| 31 Jul 17 | 17 | -5 | 8 | 4 |
| 30 Apr 17 | 15 | -7 | 8 | 4 |
| 31 Jan 17 | 15 | -7 | 8 | 4 |
| 31 Oct 16 | 14 | -8 | 8 | 4 |
| 31 Jul 16 | 12 | -10 | 9 | 4 |
| 30 Apr 16 | 11 | -10 | 9 | 4 |
| 31 Jan 16 | 12 | -12 | 9 | 4 |
| 31 Oct 15 | 11 | -12 | 9 | 4 |
| 31 Jul 15 | 10 | -13 | 9 | 5 |
| 30 Apr 15 | 9 | -13 | 10 | 5 |
| 31 Jan 15 | 8 | -12 | 10 | 4 |
| 31 Oct 14 | 10 | -10 | 11 | 4 |
| 31 Jul 14 | 10 | -9 | 10 | 3 |
| 30 Apr 14 | 12 | -7 | 9 | 2 |
| 31 Jan 14 | 11 | -7 | 8 | 2 |
Kwaliteitswinsten: CSBR is currently unprofitable.
Groeiende winstmarge: CSBR is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CSBR is unprofitable, and losses have increased over the past 5 years at a rate of 52.7% per year.
Versnelling van de groei: Unable to compare CSBR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CSBR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-10.7%).
Rendement op eigen vermogen
Hoge ROE: CSBR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.